ENSYSCE BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.63 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-30
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $2.83.
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $1.01.
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $2.63.
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $13.98, a 93.95% decline from fiscal 2022.
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $230.89.
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $2.63 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $2.63 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | $2.63 10-Q · filed 2025-08-13 | ||||
| 2025-03-31 | $2.83 10-Q · filed 2025-05-13 | ||||
| 2023-12-31 | $13.98 10-K · filed 2025-03-10 | $0.93 10-K · filed 2024-03-15 | |||
| 2023-06-30 | $0.96 10-Q · filed 2023-08-11 | ||||
| 2022-12-31 | $230.89 10-K · filed 2024-03-15 | $19.24 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $19.24 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | $0.96 10-Q · filed 2022-08-11 | ||||
| 2022-03-31 | $1.01 10-Q · filed 2023-05-15 | ||||
| 2021-12-31 | $0.00 10-K · filed 2022-03-31 | ||||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-16 | ||||
| 2020-12-31 | $2.20 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $2.20 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | $2.21 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |